Stock SIGHT GENSIGHT BIOLOGICS S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings GenSight Biologics S.A.

Equities

SIGHT

FR0013183985

Market Closed - Euronext Paris
Other stock markets
 11:35:19 2024-04-30 am EDT 		5-day change 1st Jan Change
0.395 EUR -3.66% Intraday chart for GenSight Biologics S.A. -5.84% -14.13%
Apr. 05 GenSight: financial visibility assured until the end of April CF
Mar. 25 GenSight: share price falls, limited financial visibility CF

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • Low profitability weakens the company.
  • One of the major weak points of the company is its financial situation.
  • Based on current prices, the company has particularly high valuation levels.
  • Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
GENSIGHT BIOLOGICS S.A. Stock GenSight Biologics S.A.
-14.13% 33.2M -
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+8.96% 105B
B+
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.43% 104B
B+
ARGENX SE Stock argenx SE
+4.40% 22.94B
B
BIONTECH SE Stock BioNTech SE
-12.15% 22.34B
B+
GENMAB A/S Stock Genmab A/S
-4.36% 19.25B
A-
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.08B
A-
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.04% 16.96B
B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.79% 14.16B
C+
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+38.61% 12.63B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. SIGHT Stock
  4. Ratings GenSight Biologics S.A.